Addition time plays a major role in the inhibitory effect of chitosan on the production of Pseudomonas aeruginosa virulence factors.
Petra KašparováS BokováM RollováM PaldrychováEva VaňkováK LokočováJ MichailiduOlga MaťátkováJan MasákPublished in: Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] (2022)
Pseudomonas aeruginosa is a gram-negative bacterium capable of forming persistent biofilms that are extremely difficult to eradicate. The species is most infamously known due to complications in cystic fibrosis patients. The high mortality of cystic fibrosis is caused by P. aeruginosa biofilms occurring in pathologically overly mucous lungs, which are the major cause facilitating the organ failure. Due to Pseudomonas biofilm-associated infections, remarkably high doses of antibiotics must be administered, eventually contributing to the development of antibiotic resistance. Nowadays, multidrug resistant P. aeruginosa is one of the most terrible threats in medicine, and the search for novel antimicrobial drugs is of the utmost importance. We have studied the effect of low molecular weight chitosan (LMWCH) on various stages of P. aeruginosa ATCC 10145 biofilm formation and eradication, as well as on production of other virulence factors. LMWCH is a well-known naturally occurring agent with a vast antimicrobial spectrum, which has already found application in various fields of medicine and industry. LMWCH at a concentration of 40 mg/L was able to completely prevent biofilm formation. At a concentration of 60 mg/L, this agent was capable to eradicate already formed biofilm in most studied times of addition (2-12 h of cultivation). LMWCH (50 mg/L) was also able to suppress pyocyanin production when added 2 and 4 h after cultivation. The treatment resulted in reduced formation of cell clusters. LMWCH was proved to be an effective antibiofilm agent worth further clinical research with the potential to become a novel drug for the treatment of P. aeruginosa infections.
Keyphrases
- biofilm formation
- pseudomonas aeruginosa
- cystic fibrosis
- multidrug resistant
- candida albicans
- staphylococcus aureus
- gram negative
- acinetobacter baumannii
- end stage renal disease
- lung function
- drug delivery
- chronic kidney disease
- escherichia coli
- drug resistant
- risk factors
- newly diagnosed
- helicobacter pylori infection
- stem cells
- peritoneal dialysis
- climate change
- wound healing
- risk assessment
- type diabetes
- cell therapy
- bone marrow
- prognostic factors
- cardiovascular events
- combination therapy
- electronic health record
- helicobacter pylori
- human health
- antimicrobial resistance